Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658943 · ClinicalTrials.gov registry record · Phase 2
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT01658943: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01658943 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 137 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01658943, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Selumetinib and Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet know whether selumetinib and Akt inhibitor MK2206 are more effective than oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer.
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- DRUG Selumetinib
- DRUG Akt Inhibitor MK2206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658943
The ClinicalTrials.gov registry entry for NCT01658943 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluorouracil is the first listed.
NCT01658943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658943 about?
NCT01658943 is a clinical study titled "Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy". This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) therapy in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Selumetinib and Akt inhibito...
What is the current status of trial NCT01658943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2012-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01658943?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Selumetinib (DRUG), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01658943?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.